Ikarian Capital
Latest statistics and disclosures from Ikarian Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALNY, CLDX, AXSM, XBI, KRTX, and represent 33.89% of Ikarian Capital's stock portfolio.
- Added to shares of these 10 stocks: AXSM (+$33M), ALNY (+$20M), KRTX (+$19M), ALT (+$14M), ESPR (+$13M), RLMD (+$11M), SRPT (+$9.4M), KZR (+$9.3M), LNTH (+$6.6M), ICPT (+$5.8M).
- Started 22 new stock positions in ALT, HRMY, ARDX, INSM, RGLS, CASI, CFRX, ESPR, KDNY, ITOS. COGT, TERN, EOLS, AXSM, PRAX, FULC, VRNA, BBIO, VRDN, KWEB, LNTH, SRPT.
- Reduced shares in these 10 stocks: XBI (-$44M), NBIX (-$38M), BCYC (-$37M), GILD (-$22M), RETA (-$17M), BMRN (-$16M), UTHR (-$14M), ZNTL (-$9.3M), SAGE (-$8.1M), Biohaven Pharmaceutical Holding (-$7.1M).
- Sold out of its positions in LIFE, ACAD, ACRS, AGEN, AKBA, AMYT, Applied Genetic Technol Corp C, APTO, ASND, ASMB.
- Ikarian Capital was a net seller of stock by $-123M.
- Ikarian Capital has $548M in assets under management (AUM), dropping by -27.67%.
- Central Index Key (CIK): 0001778253
Tip: Access up to 7 years of quarterly data
Positions held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ikarian Capital
Ikarian Capital holds 115 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Call Option (ALNY) | 10.4 | $57M | +54% | 392k | 145.85 | |
| Celldex Therapeutics Com New Put Option (CLDX) | 8.2 | $45M | +12% | 1.7M | 26.96 | |
| Axsome Therapeutics Put Option (AXSM) | 5.9 | $33M | NEW | 850k | 38.30 | |
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 4.7 | $26M | -62% | 350k | 74.27 | |
| Karuna Therapeutics Ord Put Option (KRTX) | 4.6 | $25M | +300% | 200k | 126.52 | |
| Amgen Call Option (AMGN) | 4.4 | $24M | -16% | 100k | 243.30 | |
| Biogen Idec Call Option (BIIB) | 4.2 | $23M | 113k | 203.92 | ||
| Horizon Therapeutics Pub L SHS (HZNP) | 3.8 | $21M | -3% | 260k | 79.76 | |
| Kezar Life Sciences Call Option (KZR) | 3.7 | $21M | +82% | 2.5M | 8.27 | |
| Altimmune Com New Call Option (ALT) | 2.6 | $14M | NEW | 1.2M | 11.70 | |
| BioMarin Pharmaceutical Call Option (BMRN) | 2.5 | $14M | -54% | 167k | 82.88 | |
| Esperion Therapeutics (ESPR) | 2.4 | $13M | NEW | 2.1M | 6.36 | |
| Amylyx Pharmaceuticals Call Option (AMLX) | 2.1 | $12M | -7% | 597k | 19.26 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.1 | $11M | +60% | 40k | 281.77 | |
| Gossamer Bio (GOSS) | 2.0 | $11M | +33% | 1.3M | 8.37 | |
| Relmada Therapeutics Call Option (RLMD) | 2.0 | $11M | +2570% | 582k | 18.99 | |
| Bellus Health Com New Call Option (BLU) | 1.9 | $10M | +22% | 1.1M | 9.24 | |
| Milestone Pharmaceuticals Call Option (MIST) | 1.7 | $9.5M | -17% | 1.6M | 5.94 | |
| United Therapeutics Corporation (UTHR) | 1.7 | $9.4M | -60% | 40k | 235.65 | |
| Sarepta Therapeutics Call Option (SRPT) | 1.7 | $9.4M | NEW | 125k | 74.95 | |
| Sage Therapeutics Call Option (SAGE) | 1.5 | $8.1M | -49% | 250k | 32.30 | |
| Apellis Pharmaceuticals Call Option (APLS) | 1.4 | $7.5M | -5% | 165k | 45.23 | |
| Xenon Pharmaceuticals (XENE) | 1.3 | $7.3M | 239k | 30.42 | ||
| Lantheus Holdings Inc Common Stock Usd 0.01 Call Option (LNTH) | 1.2 | $6.6M | NEW | 100k | 66.02 | |
| Intercept Pharmaceuticals In (ICPT) | 1.1 | $6.3M | +1194% | 455k | 13.80 | |
| Tracon Pharmaceuticals Com New (TCON) | 1.0 | $5.6M | 2.8M | 2.00 | ||
| Reata Pharmaceuticals Cl A (RETA) | 1.0 | $5.6M | -75% | 183k | 30.38 | |
| Vaxcyte (PCVX) | 0.9 | $4.9M | -28% | 226k | 21.76 | |
| Galapagos Nv Spon Adr (GLPG) | 0.9 | $4.8M | 87k | 55.60 | ||
| Scpharmaceuticals (SCPH) | 0.8 | $4.3M | -8% | 884k | 4.82 | |
| Harmony Biosciences Hldgs In (HRMY) | 0.8 | $4.2M | NEW | 86k | 48.77 | |
| Pfizer (PFE) | 0.8 | $4.2M | 80k | 52.42 | ||
| Neurocrine Biosciences (NBIX) | 0.7 | $3.8M | -91% | 39k | 97.49 | |
| Miragen Therapeutics Call Option (VRDN) | 0.6 | $3.5M | NEW | 300k | 11.57 | |
| Kraneshares Tr Csi Chi Internet (KWEB) | 0.6 | $3.3M | NEW | 100k | 32.77 | |
| Blueprint Medicines Call Option (BPMC) | 0.6 | $3.2M | 64k | 50.50 | ||
| Athira Pharma Call Option (ATHA) | 0.5 | $3.0M | 984k | 3.05 | ||
| Iveric Bio Call Option (ISEE) | 0.5 | $2.8M | +497% | 294k | 9.62 | |
| Satsuma Pharmaceuticals Ord (STSA) | 0.5 | $2.7M | 653k | 4.14 | ||
| Insmed Com Par $.01 (INSM) | 0.4 | $2.5M | NEW | 125k | 19.72 | |
| Viking Therapeutics (VKTX) | 0.4 | $2.4M | +56% | 835k | 2.89 | |
| Cogent Biosciences (COGT) | 0.4 | $2.3M | NEW | 250k | 9.02 | |
| Adicet Bio (ACET) | 0.4 | $2.1M | -74% | 143k | 14.60 | |
| Iteos Therapeutics Call Option (ITOS) | 0.4 | $2.1M | NEW | 100k | 20.61 | |
| Lyra Therapeutics (LYRA) | 0.4 | $2.0M | -17% | 347k | 5.65 | |
| Seres Therapeutics (MCRB) | 0.3 | $1.9M | -35% | 541k | 3.43 | |
| Arcus Biosciences Incorporated Put Option (RCUS) | 0.3 | $1.9M | -51% | 73k | 25.32 | |
| Bridgebio Pharma Call Option (BBIO) | 0.3 | $1.8M | NEW | 200k | 9.09 | |
| Astria Therapeutics (ATXS) | 0.3 | $1.8M | +542% | 592k | 3.00 | |
| Terns Pharmaceuticals (TERN) | 0.3 | $1.7M | NEW | 700k | 2.48 | |
| X4 Pharmaceuticals (XFOR) | 0.3 | $1.6M | +22% | 1.7M | 0.96 | |
| Aldeyra Therapeutics (ALDX) | 0.3 | $1.5M | 375k | 3.99 | ||
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.3 | $1.4M | 317k | 4.42 | ||
| Immatics SHS (IMTX) | 0.2 | $1.4M | -79% | 157k | 8.71 | |
| Vascular Biogenics (VBLT) | 0.2 | $1.3M | 830k | 1.61 | ||
| Aadi Bioscience (AADI) | 0.2 | $1.3M | +97% | 412k | 3.09 | |
| Merus N V (MRUS) | 0.2 | $1.2M | 54k | 22.64 | ||
| Cabaletta Bio (CABA) | 0.2 | $1000k | -35% | 944k | 1.06 | |
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.2 | $992k | 268k | 3.70 | ||
| Ardelyx (ARDX) | 0.2 | $991k | NEW | 1.7M | 0.59 | |
| Anebulo Pharmaceuticals (ANEB) | 0.2 | $942k | 181k | 5.20 | ||
| Finch Therapeutics (FNCH) | 0.2 | $938k | 331k | 2.84 | ||
| Chimerix (CMRX) | 0.2 | $917k | -47% | 441k | 2.08 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $912k | -13% | 322k | 2.83 | |
| Tricida Put Option (TCDA) | 0.2 | $899k | 93k | 9.68 | ||
| Fulcrum Therapeutics Call Option (FULC) | 0.2 | $893k | NEW | 182k | 4.90 | |
| Eledon Pharmaceuticals (ELDN) | 0.2 | $884k | 363k | 2.44 | ||
| Rigel Pharmaceuticals Com New (RIGL) | 0.1 | $794k | -67% | 703k | 1.13 | |
| Clovis Oncology (CLVSQ) | 0.1 | $761k | -45% | 422k | 1.80 | |
| Ayala Pharmaceuticals Incorporated (AYLA) | 0.1 | $759k | 697k | 1.09 | ||
| Protara Therapeutics Com Stk (TARA) | 0.1 | $756k | -13% | 258k | 2.93 | |
| Aileron Therapeutics | 0.1 | $752k | 2.9M | 0.26 | ||
| Gemini Therapeutics | 0.1 | $749k | 443k | 1.69 | ||
| Brainstorm Cell Therapeutics Com New (BCLI) | 0.1 | $698k | -16% | 253k | 2.75 | |
| Pardes Biosciences (PRDS) | 0.1 | $687k | -30% | 224k | 3.07 | |
| Bellicum Pharmaceuticals Com New (BLCM) | 0.1 | $617k | 523k | 1.18 | ||
| Contrafect Corp Com New Put Option (CFRX) | 0.1 | $615k | NEW | 200k | 3.08 | |
| Synaptogenix Com New (SNPX) | 0.1 | $614k | -20% | 121k | 5.07 | |
| Renovacor | 0.1 | $595k | -14% | 293k | 2.03 | |
| Connect Biopharma Hldgs Ads (CNTB) | 0.1 | $591k | 678k | 0.87 | ||
| Inhibrx (INBX) | 0.1 | $561k | -79% | 49k | 11.36 | |
| Synlogic (SYBX) | 0.1 | $545k | -8% | 474k | 1.15 | |
| Evolus (EOLS) | 0.1 | $529k | NEW | 46k | 11.62 | |
| Reneo Pharmaceuticals (RPHM) | 0.1 | $491k | 186k | 2.65 | ||
| Immunic (IMUX) | 0.1 | $428k | +100% | 123k | 3.48 | |
| Casi Pharmaceuticals Com New (CASI) | 0.1 | $378k | NEW | 132k | 2.86 | |
| Nextcure (NXTC) | 0.1 | $336k | -49% | 71k | 4.70 | |
| Wave Life Sciences SHS (WVE) | 0.1 | $318k | -90% | 98k | 3.24 | |
| Zai Lab Adr (ZLAB) | 0.1 | $278k | -39% | 82k | 3.40 | |
| Verastem (VSTM) | 0.0 | $265k | -66% | 228k | 1.16 | |
| Praxis Precision Medicines I Call Option (PRAX) | 0.0 | $263k | NEW | 107k | 2.45 | |
| Immunoprecise Antibodies Com New (IPA) | 0.0 | $237k | -20% | 61k | 3.86 | |
| Hepion Pharmaceuticals (HEPA) | 0.0 | $235k | -29% | 410k | 0.57 | |
| Corbus Pharmaceuticals Hldgs (CRBP) | 0.0 | $217k | -13% | 863k | 0.25 | |
| Regulus Therapeutics (RGLS) | 0.0 | $217k | NEW | 105k | 2.06 | |
| Verona Pharma Sponsored Ads (VRNA) | 0.0 | $200k | NEW | 300k | 0.67 | |
| Mereo Biopharma Group Ads (MREO) | 0.0 | $199k | -32% | 616k | 0.32 | |
| Yumanity Therapeutics | 0.0 | $190k | -55% | 104k | 1.82 | |
| Aslan Pharmaceuticals Ads (ASLN) | 0.0 | $185k | 971k | 0.19 | ||
| Clene Common Stock (CLNN) | 0.0 | $177k | -86% | 70k | 2.53 | |
| Mymd Pharmaceuticals (MYMD) | 0.0 | $176k | -38% | 81k | 2.17 | |
| Mustang Bio (MBIO) | 0.0 | $145k | -54% | 247k | 0.59 | |
| Tempest Therapeutics (TPST) | 0.0 | $132k | 62k | 2.13 | ||
| Stealth Biotherapeutics Corp Sponsored Ads | 0.0 | $127k | 502k | 0.25 | ||
| Cyclacel Pharmaceuticals (CYCC) | 0.0 | $113k | 105k | 1.08 | ||
| Larimar Therapeutics (LRMR) | 0.0 | $100k | 52k | 1.94 | ||
| Inventiva Sa Ads (IVA) | 0.0 | $93k | 16k | 5.97 | ||
| Bright Minds Biosciences (DRUG) | 0.0 | $86k | 106k | 0.81 | ||
| Mind Medicine Mindmed Com Sub Vtg | 0.0 | $68k | 106k | 0.64 | ||
| Ovid Therapeutics (OVID) | 0.0 | $59k | -96% | 27k | 2.20 | |
| Enveric Biosciences Com New | 0.0 | $48k | -47% | 224k | 0.21 | |
| Altamira Therapeutics SHS | 0.0 | $36k | -76% | 75k | 0.48 | |
| Baudax Bio Com New | 0.0 | $3.0k | 3.0k | 1.01 | ||
| Otonomy (OTIC) | 0.0 | $0 | -99% | 180.00 | 0.00 | |
| Chinook Therapeutics (KDNY) | 0.0 | $0 | NEW | 332k | 0.00 |
Past Filings by Ikarian Capital
SEC 13F filings are viewable for Ikarian Capital going back to 2019
- Ikarian Capital 2022 Q2 filed Aug. 12, 2022
- Ikarian Capital 2022 Q1 filed May 13, 2022
- Ikarian Capital 2021 Q4 filed Feb. 14, 2022
- Ikarian Capital 2021 Q3 filed Nov. 15, 2021
- Ikarian Capital 2021 Q1 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 filed Aug. 16, 2021
- Ikarian Capital 2021 Q1 filed May 17, 2021
- Ikarian Capital 2020 Q4 filed Feb. 12, 2021
- Ikarian Capital 2020 Q3 filed Nov. 16, 2020
- Ikarian Capital 2020 Q2 filed Aug. 14, 2020
- Ikarian Capital 2020 Q1 filed May 15, 2020
- Ikarian Capital 2019 Q4 filed Jan. 31, 2020